Cell free protein expression is also known as cell-free protein synthesis, in vitro translation, cell-free translation or in vitro protein expression. It is a well-developed, rapid, and efficient technique for synthesizing proteins in cell lysates rather than cultured cells. Cell free protein expression uses translation machineries to extract the desired cells. It can be done by using various kind of mammalian cells, bacteria, plants, and insect cells over conventional in vivo method. For instance, cell free protein expression system works independently and is free of any cellular context, owing to these benefits it is ideal for high-throughput screening of mutagenesis. Moreover, the whole machinery of cell free expression system sets better environment to manufacture membrane proteins, toxic proteins, and proteins that can get easily degraded. Pharmaceutical and biotechnological industries actively utilize these tools for research and developmental activities as well as for genomics and proteomics. Thus, it is a key factor propelling the cell free protein expression market growth over the forecast period.
Request a sample copy of this report:https://www.coherentmarketinsights.com/insight/request-sample/1082
Increasing outsourcing of cell free protein expression is expected boost the growth of cell free protein expression market
Growth of cell free expression systems is mainly driven by increasing novel approaches to the development of robust, rapid, and cost effective protein expression technique. Moreover, acquisitions is enabling market consolidation. For instance, in July 2017, Sanofi Pasteur acquired Protein Science Company to strengthen its recombinant-based influenza vaccine portfolio. Protein Science’s insect cell-based baculovirus expression vector system (BEVS) is a protein expression technology to develop recombinant protein vaccines. According to Sanofi, BEVS is rapid and cost effective system than other production system. This acquisition is expected to broaden Sanofi’s flu portfolio and technological strength.
In September 2017, iBio, Inc. with its subsidiary iBio CDMO LLC, a contract development and manufacturing organization (CDMO) collaborated with TheoremDx, Inc. to develop proteins for rapid diagnostic testing products. The collaboration aims to offer plant proteins through robust development and manufacturing in the U.S. and other economies. iBio is expected to provide an expression system to TheoremDx, which allows establishment of new diagnostics through cGMP scale-up production. Both iBio and TheoremDx are specifically focusing on development of rapid diagnostic tests, which can help in identifying and distinguishing neglected tropical diseases such as Zika, West Nile, Dengue, and Chikungunya. This collaboration is a major strategic step for advancement of rapid detection test internationally. Such initiatives and investments are expected to fuel the growth of cell free protein expression market over the forecast period.
However, high cost, low yield of protein from certain species, lack of eukaryotic co- and post-translational modifications. For instance, cell free system based on E.coli and wheat germ extracts has some limitation to produce human proteins with post translation modifications (PTMs). This acts as a restraint for the cell free protein expression market growth.
Access Table of Content (TOC) Of the Report: https://www.coherentmarketinsights.com/ongoing-insight/toc/1082
Key players in the global cell free protein expression market include 3P Biopharmaceuticals, Sanofi Pasteur, Oxford Expression Technologies, Abnova, Thermo Fisher Scientific, iBio CDMO LLC, Protein Science Company, Profacgen, Research Corporation Technologies, and Cambridge Isotope Laboratories, Inc. (CIL).